From mRNA to Cure
Our OneRNA platform enables repurposing of existing drugs on an individual patient basis and the development of individualized novel RNA therapeutics e.g. RNA vaccines to develop Next Generation Cures.
ARE YOU A DOCTOR OR A PATIENT ?
Looking for better treatment options for your patients? Our OneRNA Platform enables repurposing existing drugs on an individual patient basis
ARE YOU DEVELOPING CURES?
Using just one biomarker can save $1B during clinical development.
The OneRNA Platform makes the companion diagnostic into an algorithm and rapidly translates RNA code to novel RNA Theraputics
RNA Platform
By analyzing RNA we can monitor health, detect disease and design next generation cures
DNA is not your fate. RNA is coding for proteins and proteins are targets for drugs, today RNA is directly a target for drugs and a drug itself. We are experts in analyzing RNA using Next Generation Sequencing and translating RNA Code to RNA Therapeutics to individualize treatment
OneRNA® for treatment selection in cancer
DNA is not your fate. RNA codes for proteins and proteins are targets for drugs, furthermore today RNA is directly a target for drugs and a drug itself. We coded all that information into our OneRNA® platform and initiated 3 clinical studies to produce supporting data.
Detect
Substituting the use of cystoscopy for the detection of bladder cancer
Treat
Treat based on OneRNA rather than standard of care
Monitor
Monitor effectiveness of treatment in simple urine test
Individualize
Optimize treatment real time to prevent recurrence and ineffective treatments
WHO WE ARE
Experienced Management Team with Startup RNA
Gitte Pedersen
CEO and co-founder
Gitte Pedersen, CEO is a former executive at NovoZymes, the world’s largest enzyme manufacturer. She has advised the Danish Government and early stage biotech companies regarding their corporate development in the US
Follow at DNABARCODE
What our Customers say
We work with corporations and governments to enable safe reopening our economy
Laura Dinsmore, President and CEO
Quadrant Health Strategies, Inc.
"We highly value our collaboration with Genomic Expression. We have worked with them since they launched COVID19 testing and have been impressed with their turnaround time and extraordinary customer service, consistently stepping up, often on short notice"
Mike Horrocks, CEO
EREMA North America, Inc.
" Access to rapid and accurate COVID19 testing for our employees is critical in allowing us to keep our facility open and to support our customers. It allows our employees to be confident in the work environment . Genomic Expressions ease of use, turnaround time, support and service has been essential in helping to reduce the risks in continuing our business model "
WHO'S TALKING ABOUT US
We have been featured in Forbes twice, GEN, GenomeWeb and MedWatch. Our investors include Biogen founders, Harvard Business Angels, Investor Circle, Pipeline Angels, and a family office; Centurion Holding in New York.
We are a Springboard alum company and among the 500 women-owned technology companies they have supported. Genomic Expression came in #2 in the Women’s Founders Pitch event in LA, was in the top 10 companies to pitch for Sir Richard Branson (Virgin Airlines) Extreme Technology Challenge, and was invited to dinner with Branson on Necker’s Island.
We have brought the company from idea to commercialization for grants, revenue, and angel funding, and are now implementing capabilities to rapidly translate RNA code to novel RNA Theraputics in collaborations with Biotech and Pharma
This is our founder's story:
Articles, Grants, Investors and Customers
These are our supporters, funders and customers
In the semi-finals of the XPRIZE for Rapid Covid Testing - $6 million dollar, 6-month competition to develop faster, cheaper, and easier to COVID-19 testing methods at scale.
WANT TO LEARN MORE ?
DISCLAIMER
The information contained in our website is for general reference only, and should not be relied upon for any medical decision, or as a recommendation for any course of medical treatment. By 'opting-in' to our website, you understand we are not undertaking any responsibility to provide you with medical advice of any kind or character. There is no representation as to the accuracy or completeness of the information on our website, and we have no obligation to update or correct any posted information.
TALK BACK
Follow us on twitter
@2020